Financials data is unavailable for this security.
Inc stmt in DKKIncome statement in DKK
Year on year
Novo Nordisk A/S had little change in net income (from 38.63bn to 38.95bn) despite revenues that grew 9.11% from 111.83bn to 122.02bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 15.75% to 16.03%.
|Net profit margin||32.73%|
|Return on assets||32.62%|
|Return on equity||73.24%|
|Return on investment||63.67%|
Cash flow in DKK
Novo Nordisk A/S did not generate a significant amount of cash. However, the company earned 46.78bn from its operations for a Cash Flow Margin of 38.34%. In addition the company used 11.51bn on investing activities and also paid 35.48bn in financing cash flows.
|Cash flow per share||20.01|
|Price/Cash flow per share||16.80|
|Book value per share||26.09|
|Tangible book value per share||23.58|
Balance sheet in DKK
|Total debt/total equity||0.069|
|Total debt/total capital||0.0645|
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 2.45% and 2.78%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||2.37%|
|Div growth rate (5 year)||10.80%|
|Payout ratio (TTM)||37.28%|
|EPS growth(5 years)||10.22|
|EPS (TTM) vs |
TTM 1 year ago